Advanced Enzymes Fundamental Snapshot

Reading Time: 2 minutes

Let’s dig deeper into the Advanced Enzymes fundamental analysis.

Advanced Enzymes Business: Manufacturing of Enzymes and Probiotics

Enzyme: Biocatalyst that increases reaction rate (Like in various ads we have seen –“with Added Enzyme)

  • Human Nutrition, Animal Nutrition, Food Processing & Non-Food Processing
  • Enzymes are used in Human Health Care and nutrition, Animal nutrition, Fruit and vegetable processing, dairy processing, textile processing, leather processing, paper, and pulp processing, etc.
  • Nutrition linked product importance have more important Due to Covid19
  • Incorporated as Advanced Biochemicals Pvt Ltd in 1989.
  • 400+ self-owned products developed from 68+ indigenous enzymes.
  • Largest Indian Enzyme Company
  • Amongst Top 15 Global Enzyme Companies, Customers worldwide 700+
  • Presence in 45+ countries (although Revenue 80% from USA and India)

Management: (Experienced and management has been with the company since long)

Chairman and Promoter – VL Rathi (37 years of experience in the enzyme industry)

– CFO-Beni Prasad Rauka ( CA and CS) with the company for 24 years

-R&D head- Dr. Anil Kumar Gupta Ph.D. in Microbiology with 18 years experience in Industrial biology

(Joined Advanced Enzyme in 1996 as junior research associate)

Also Read on FinMedium:  8 Low-Risk Investment Options if you are a low-risk Investor

Important Highlights:

  • Revenue share 57% international and 43% India (42% for USA, India 43%, Rest 15%)
  • 76% from Human Nutrition ( Act as trigger after Covid19),12% Animal Nutrition and 12% Industrial Bio-Processing.
  • Subsidiary companies – Advanced Enzyme USA Inc, Advanced Enzytech solution, Advanced Bio-Agro Tech Ltd., JC Biotech Pvt Ltd, Advanced Enzymes Malaysia & Advanced Enzyme Europe
  • 7 Manufacturing plants– 5 in India and 2 in the USA.
  • Promoter holding: 57.9%, Mutual Funds 8.78%(HDFC Small cap 6.84%), FPI 11.1%

FPI+Mutual Funds stake rose from just 6.81% on 31 March 2018 to 19.9% on 31st March 2020.

FPI and Mutual funds have a heavy stake in it (Very positive)


  • Revenue has grown in 5 years with CAGR of 15% while profit at 21%.
  • Debt during 5 years has reduced from 115 cr in FY15 to just 25cr in FY20 i.e. have become virtually debt-free, against the reserve of 817cr( DE ratio just 0.03).
  • During the same time companies, Fixed assets increased by 281cr that shows the company is generating good cash flows.
  • EBITDA Margin is good at 46% in FY20 which rose from 42% in FY18.
  • Net working capital cycle also has been in the range from around 115 days.
  • R&D expenditure as % of Net sales stands at 3.24% which is also a good sign.
  • CFO rose from 53cr to 141 cr at the same time.
  • ROCE 23%, ROE 18%, Trading at PE of 14.4, and PB of 2.2.
Also Read on FinMedium:  A 5-Weeks Course on Pharma Sector - Week 1

Arman’s Linkedin Profile

Disclaimer: The opinions expressed in this publication are those of the authors. They do not purport to reflect the opinions or views of the FinMedium or its members. The presentation of material therein does not imply the expression of any opinion whatsoever on the part of the FinMedium concerning the legal status of any company, country, area, or territory or of its authorities. For more info. please read our ToU & Privacy Policy here. If you have any concerns regarding this post, please reach out to us at

Every Wednesday and Saturday, we send Info-Graphic and FinMedium Weekly Digest newsletters to our 25000+ Subscribers.

Join Them Now!

Arman Nahar

Arman Nahar

C.A. who is a USA CFA L3 candidate | Cleared L1 & L2 | Doing independent equity research since 2016 | Screens stocks for investment | Makes in-depth valuation models | Crafts portfolios.
Please Share Now :)